Category: 39069-02-8

Reference of 39069-02-8, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.39069-02-8, Name is 2,9-Dibromo-1,10-phenanthroline, molecular formula is C12H6Br2N2. In a Patent，once mentioned of 39069-02-8

The present invention provides a rare earth metal complex represented by the following formula (I).

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 39069-02-8

Reference：
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Electric Literature of 39069-02-8, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.39069-02-8, Name is 2,9-Dibromo-1,10-phenanthroline, molecular formula is C12H6Br2N2. In a Article，once mentioned of 39069-02-8

Seven acyclic tetradentate compounds of varying lipophilicity incorporating two nitrogen and two alkyl or aryl phosphinate donors have been prepared and their complexation of divalent ions has been studied in aqueous solution by pH-metric, NMR and electrospray mass spectrometric methods of analysis. The hard phosphinate oxygen donor favours binding to the charge-dense Mg2+ ion but binds copper(II) only very weakly in solution. Nickel and zinc ions do form 1:1 complexes involving significant phosphinate ligation and this donor-atom preference leads to an inversion of the Irving-Williams stability sequence.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 39069-02-8

Reference：
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent， Recommanded Product: 2,9-Dibromo-1,10-phenanthroline, Which mentioned a new discovery about 39069-02-8

The invention provides a nerve of surgical medicine temazepam intermediate compound of the formula (III) compound synthetic method, the synthetic method is as follows: in the catalyst, ligand, in the presence of alkali and accelerator, the following formula (I) compounds of the formula (II) compound in the organic solvent in the reaction, after-treatment after the reaction, so as to obtain states the type (III) compounds, the synthesis method through the unique reaction system, but can yield to obtain the target product. The invention also provides the above-mentioned compound recrystallization purification method, through the unique the re-crystallization method, can significantly improve the purity of the product, for the compound to provide new method for the purification of, and has good application prospect and potential. (by machine translation)

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, Recommanded Product: 2,9-Dibromo-1,10-phenanthroline, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 39069-02-8

Reference：
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, Safety of 2,9-Dibromo-1,10-phenanthroline, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 39069-02-8, Name is 2,9-Dibromo-1,10-phenanthroline, molecular formula is C12H6Br2N2. In a Article, authors is Zhang, Lili，once mentioned of 39069-02-8

Synthesis and computation of diastereomeric phenanthroline-quinine ligands and their application in asymmetric Henry reaction

A class of chiral ligands has been developed by combining phenanthroline with quinine in a one-step method that does not require resolution. The synthesized three ligands were then coordinated with Cu(II) and the performance of the resultant chiral catalysts in the asymmetric Henry reaction was evaluated. Moderate to good yields (up to 86%) with high enantioselectivities (up to 99% ee) were observed in the reactions catalyzed by one of the three catalysts. Theoretical calculations were performed to analyze the catalytic activities of the different Cu(II)-ligand catalysts. Three different ligands were investigated and one ligand was found to adopt an unexpected five-coordinated mode; the second coordinated with two nitrogen atoms of phenanthroline to give a complex, which activated both substrates of Henry reaction; the third was unable to form a complex with Cu(II).

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 39069-02-8, help many people in the next few years.Safety of 2,9-Dibromo-1,10-phenanthroline

Reference：
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

39069-02-8, 2,9-Dibromo-1,10-phenanthroline is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

31.9 g (0.101 mol) of intermediate 233-3 was dissolved in 320 ml of toluene solvent.Stir under nitrogen,16 g (0.0505 mol) of 2,9-dibromo-phenanthroline 19.6 g (0.202 mol) was added in sequence.Sodium tert-butoxide, 0.45 g (0.000505 mol) (DBA) 3Pd21.01 ml (0.000505 mol) of tri-tert-butylphosphine, heated to reflux.After 6 hours of reaction, the reaction was completed, the reaction was stopped, and the reaction solution was dried under reduced pressure.The residue obtained was recrystallized from xylene to give 20.3 g of Compound 233 (yield 52%)., 39069-02-8

39069-02-8 2,9-Dibromo-1,10-phenanthroline 15448099, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Beijing Lv Ren Science And Technology Co., Ltd.; Lv Yao; Feng Yu; Jia Xueyi; (53 pag.)CN108659010; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.39069-02-8,2,9-Dibromo-1,10-phenanthroline,as a common compound, the synthetic route is as follows.

Reference Example 1(2,9-bis(6-((Methoxymethyloxy)methyl)pyridine-2-yl)-1,10-phenanthroline) (20)[0109] [Chem. 15] [0110] Under a stream of argon, 2,9-dibromo-1,10-phenanthroline (compound (10); 3.25 g; 9.6 mmol) was dissolved in anhydrous dimethylformamide (45 mL). To the reaction mixture, 2-methoxymethyloxymethylpyridine-6-yl tributyltin (compound (12); 17 g; 9.6 mmol) and triphenylphosphine palladium dichloride (3.83 g; 4.8 mmol) were added, followed by stirring at 70 oC for 22 hours. The reaction mixture was cooled to room temperature, and Rochelle salt was added thereto. Subsequently, the reaction mixture was poured into saline, and ethyl acetate was added thereto. Insoluble matters were filtered out, and the filtrate was extracted with ethyl acetate. The organic layer was washed with water and saturated saline, dried over anhydrous sodium sulfate, and then evaporated under reduced pressure to give oil matters. Under a stream of argon, the resulting oil matters were dissolved in anhydrous dimethylformamide (45 mL), and compound (12) (17 g; 9.6 mmol) and triphenylphosphine palladium dichloride (2.72 g; 3.38 mmol) were added thereto, followed by stirring at 70 oC for 20 hours. The reaction mixture was cooled to room temperature, and Rochelle salt was added thereto. Subsequently, the reaction mixture was poured into saline, and ethyl acetate was added thereto. Insoluble matters were filtered out, and the filtrate was extracted with ethyl acetate. The organic layer was washed with water and saturated saline, dried over anhydrous sodium sulfate, and then evaporated under reduced pressure to give a residue. The resulting residue was separated and purified by silica gel column chromatography (SiO2, 200 g; developing solvent: chloroform/methanol = 30/1 to 20/1 to 10/1), to give 1.1 g (yield: 23.7%) of the title compound (20).[0111] 1H NMR (DMSO-d6)d: 3.38 (s, 3 H), 4.80-4.83 (m, 8 H), 7.64 (d, J = 8 Hz, 2 H), 8.07-8.20 (m, 4 H), 8.65-8.84 (m, 4 H), 8.92 (d, J = 7 Hz, 1 H)HPLC mobile phase: 40-95% acetonitrile – water (0.1% trifluoroacetic acid)Peak retention time: 5.7 minutesESIMS (positive) m/z 483.1, (M+H) (F.W = 482.53 for C28H26N4O4), 39069-02-8

As the paragraph descriping shows that 39069-02-8 is playing an increasingly important role.

Reference£º
Patent; B.R.A.H.M.S GmbH; HOSHINO, Mikio; YANO, Toshisada; YAMANAKA, Yasukazu; WO2012/124310; (2012); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.39069-02-8,2,9-Dibromo-1,10-phenanthroline,as a common compound, the synthetic route is as follows.,39069-02-8

To 1 mL of the solution of silver(I) tetrafluoroborate (1.17 mg, 0.00601 mmol) in dichloromethane was added 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (3.48 mg, 0.00601 mmol), and the mixture was stirred at room temperature for 15 minutes. Then, f23 (2.03 mg, 0.00601 mmol) was added to the reaction solution, which was stirred at 40C for five minutes. The reaction solution was subjected to recrystallization by slow diffusion of dichloromethane-ether and dried to provide 5.40 mg of the complex of the pale yellow crystal. [Show Image] The NMR data of the obtained complex is provided below. 1H NMR (300 MHz, CDCl3) delta 8.50 (brd, 2H), 8.13 (brs, 2H), 7.84 (brd, 2H), 7.62 (brd, 2H), 7.26-7.04 (m, 22H), 6.78 (br, 2H), 1.71 (s, 6H); 31P NMR (122 MHz, CDCl3); 31P NMR (122 MHz, CDCl3) delta -4.9 (d, J (31P-107Ag, 109Ag) = 392, 451 Hz). The composition of the obtained complex was determined according to the same method as in Example 15. The present complex corresponds to the above composition formula (5).

39069-02-8 2,9-Dibromo-1,10-phenanthroline 15448099, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Sumitomo Chemical Company, Limited; EP2360162; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI